The atopic dermatitis (AD) treatment landscape is witnessing intensified competition with several novel therapies nearing market entry. While biologics like dupilumab have already transformed care, ...

Series C round led by Deep Track Capital with participation from additional new and existing investorsFinancing will fund early-to-mid-stage ...

Medically reviewed by Casey Gallagher, MD Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with ...

Atopic Dermatitis AD and Contact Dermatitis CD are skin conditions that lead to skin inflammation however their causes and ...

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

A patch test for atopic dermatitis helps identify triggers and confirms diagnosis. Learn about self-testing and specialists who perform testing.

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

If you have atopic dermatitis (eczema), this guide will help you prepare for what to except during your initial doctor's appointment, including questions to ask, tests that might be ordered, and how ...

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious ...

With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...